Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Neoplasms

Digestive System Diseases

Rare Diseases

Diabetes Mellitus, Type 2

Adenocarcinoma

Diabetes Mellitus

Pancreatic Neoplasms

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Pancreatic Cancer

1. Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)
2. Control Group: without exposure; patients over 60 years, without diabetes.

Dóra Illés, MD

László Czakó, MD, PhD, DSc

Péter Hegyi, MD, PhD, DSc

The aim of this study is to accomplish the early diagnosis of pancreatic cancer, in patients over 60 years of age with newly diagnosed diabetes. Only patients with type 2 diabetes are meant to be included. The early diagnosis of pancreatic cancer could be the way to enable efficient cure for the patients.

The prognosis of pancreatic cancer is extremely unpleasant, which can be characterized with a 5-year survival rate of only about 6%. The disease usually pertaining no symptoms at the early phase, this might be one of the causes why it is discovered at a relatively late, inoperable stage - in most of the cases. The success of reducing the high mortality rate of pancreatic cancer could depend on the significant development of early diagnosis and also prevention programs. As the lifetime prevalence of pancreatic cancer is only 1.39%, screening through the whole population would be extremely expensive and difficult to manage. It would be recommended for all the individuals at high risk for pancreatic cancer to be examined. Patients newly diagnosed with diabetes have an approximately 8-fold risk for developing this type of cancer, compared to the average population. In addition to this age is also known as an independent risk factor for the pancreatic cancer. Recently there has been a biomarker panel identified, which may distinguish between pancreatic cancer and chronic pancreatitis in patients, with high sensitivity and specificity. The aim of this study is to accomplish the early diagnosis of pancreatic cancer, in patients over 60 years of age with newly diagnosed diabetes mellitus using a specific biomarker panel. Only patients with type 2 diabetes are meant to be included. Diabetes is classified by determining C-peptide levels, representing the endogenous insulin synthesis, also detecting glutamic acid decarboxylase (GADA) antibodies, the autoantibody against the pancreatic islet cells. The early diagnosis of pancreatic cancer could be the way to enable efficient cure for the patients.

C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to classify diabetes CA 19-9 will be taken at every 12 months Blood to biobank will be taken at every 12 months. Biomarkers will be determined comparing metabolite levels in plasma samples from patients diagnosed with pancreatic cancer and diabetic cancer-free patients.

The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly

New Onset of DiabetEs in aSsociation With Pancreatic Cancer

This will be evaluated using yes/no questions on carcinoma ductale, then the data will be summarized in order to determine the incidence.

This will be evaluated using yes/no questions as part of a questionnaire filled out by the doctor who examines the patients.

Will be appraised after collecting and summarizing all the collected medical information.

Measuring the body weight of the patient and the data is recorded in the questionaire.

According to the anwers of the patients recorded on the questionnaire.

According to the physical examinations and laboratory parameters also the anwers of the patients recorded on the questionnaire

Healthcare cost spent on each patient will be calculated by a healthcare economist after the trial is completed.

Spots Global Cancer Trial Database for diabetes type2